Zacks Research Has Bullish Outlook for GSK FY2027 Earnings

GSK plc (NYSE:GSK - Free Report) - Zacks Research increased their FY2027 EPS estimates for shares of GSK in a research note issued on Tuesday, March 25th. Zacks Research analyst E. Bagri now expects that the pharmaceutical company will earn $5.05 per share for the year, up from their prior estimate of $5.04. The consensus estimate for GSK's current full-year earnings is $4.14 per share.

Other equities analysts have also issued research reports about the company. Morgan Stanley started coverage on GSK in a research note on Wednesday, February 12th. They issued an "equal weight" rating on the stock. StockNews.com raised shares of GSK from a "buy" rating to a "strong-buy" rating in a research note on Friday, February 7th. Seven equities research analysts have rated the stock with a hold rating and four have issued a strong buy rating to the company's stock. According to MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $43.25.

GSK Trading Down 1.3 %

GSK traded down $0.50 during trading hours on Thursday, reaching $38.25. The company's stock had a trading volume of 2,549,228 shares, compared to its average volume of 4,845,272. The stock has a market cap of $79.16 billion, a PE ratio of 24.05, a P/E/G ratio of 1.12 and a beta of 0.58. GSK has a fifty-two week low of $31.72 and a fifty-two week high of $45.92. The company has a debt-to-equity ratio of 1.12, a current ratio of 0.78 and a quick ratio of 0.52. The business's 50-day moving average is $37.22 and its 200-day moving average is $36.69.

Remove Ads

GSK (NYSE:GSK - Get Free Report) last released its quarterly earnings data on Wednesday, February 5th. The pharmaceutical company reported $0.59 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.44 by $0.15. GSK had a net margin of 8.13% and a return on equity of 48.59%.

GSK Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Thursday, April 10th. Investors of record on Friday, February 21st will be paid a dividend of $0.3932 per share. This is an increase from GSK's previous quarterly dividend of $0.39. This represents a $1.57 annualized dividend and a yield of 4.11%. The ex-dividend date is Friday, February 21st. GSK's dividend payout ratio is presently 98.74%.

Institutional Investors Weigh In On GSK

Hedge funds have recently added to or reduced their stakes in the business. United Bank boosted its holdings in GSK by 7.3% in the third quarter. United Bank now owns 25,785 shares of the pharmaceutical company's stock valued at $1,054,000 after purchasing an additional 1,760 shares during the period. Thrivent Financial for Lutherans raised its position in GSK by 3.4% in the 3rd quarter. Thrivent Financial for Lutherans now owns 53,348 shares of the pharmaceutical company's stock valued at $2,181,000 after purchasing an additional 1,737 shares in the last quarter. Charles Schwab Investment Management Inc. boosted its stake in shares of GSK by 13.7% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 121,603 shares of the pharmaceutical company's stock valued at $4,971,000 after buying an additional 14,687 shares during the period. Larson Financial Group LLC grew its position in shares of GSK by 527.4% during the third quarter. Larson Financial Group LLC now owns 1,807 shares of the pharmaceutical company's stock worth $74,000 after buying an additional 1,519 shares in the last quarter. Finally, The Manufacturers Life Insurance Company increased its stake in shares of GSK by 0.8% during the third quarter. The Manufacturers Life Insurance Company now owns 1,018,489 shares of the pharmaceutical company's stock worth $41,636,000 after buying an additional 7,990 shares during the period. 15.74% of the stock is currently owned by institutional investors and hedge funds.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.